These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 19781408)

  • 1. Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
    Cannon CP; Dansky HM; Davidson M; Gotto AM; Brinton EA; Gould AL; Stepanavage M; Liu SX; Shah S; Rubino J; Gibbons P; Hermanowski-Vosatka A; Binkowitz B; Mitchel Y; Barter P;
    Am Heart J; 2009 Oct; 158(4):513-519.e3. PubMed ID: 19781408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients.
    Bloomfield D; Carlson GL; Sapre A; Tribble D; McKenney JM; Littlejohn TW; Sisk CM; Mitchel Y; Pasternak RC
    Am Heart J; 2009 Feb; 157(2):352-360.e2. PubMed ID: 19185645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial.
    Brinton EA; Kher U; Shah S; Cannon CP; Davidson M; Gotto AM; Ashraf TB; McCrary Sisk C; Dansky H; Mitchel Y; Barter P;
    J Clin Lipidol; 2015; 9(1):65-71. PubMed ID: 25670362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
    McKenney JM; Davidson MH; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of anacetrapib in patients with or at high risk for coronary heart disease.
    Cannon CP; Shah S; Dansky HM; Davidson M; Brinton EA; Gotto AM; Stepanavage M; Liu SX; Gibbons P; Ashraf TB; Zafarino J; Mitchel Y; Barter P;
    N Engl J Med; 2010 Dec; 363(25):2406-15. PubMed ID: 21082868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Kher U; Hunter JA; Gill GG; Cressman MD; Ashraf TB; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Feb; 119(3):388-396. PubMed ID: 27956003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
    Kastelein JJ; Besseling J; Shah S; Bergeron J; Langslet G; Hovingh GK; Al-Saady N; Koeijvoets M; Hunter J; Johnson-Levonas AO; Fable J; Sapre A; Mitchel Y
    Lancet; 2015 May; 385(9983):2153-61. PubMed ID: 25743173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study.
    Gotto AM; Moon JE
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):955-63. PubMed ID: 23030283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study.
    Gotto AM; Kher U; Chatterjee MS; Liu Y; Li XS; Vaidya S; Cannon CP; Brinton EA; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):543-9. PubMed ID: 24737712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
    Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    Am J Cardiol; 2014 Jan; 113(1):76-83. PubMed ID: 24188894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL metabolism and CETP inhibition.
    Barkowski RS; Frishman WH
    Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
    Davidson MH; McKenney JM; Shear CL; Revkin JH
    J Am Coll Cardiol; 2006 Nov; 48(9):1774-81. PubMed ID: 17084249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in Japanese patients with dyslipidemia.
    Teramoto T; Daida H; Ikewaki K; Arai H; Maeda Y; Nakagomi M; Shirakawa M; Watanabe Y; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Blaustein RO
    Atherosclerosis; 2017 Jun; 261():69-77. PubMed ID: 28478132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
    Ballantyne CM; Shah S; Sapre A; Ashraf TB; Tobias SC; Sahin T; Ye P; Dong Y; Sheu WH; Kang DH; Ferreira Rossi PR; Moiseeva Y; Briones IR; Johnson-Levonas AO; Mitchel YB
    Am J Cardiol; 2017 Aug; 120(4):569-576. PubMed ID: 28624096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Arai H; Teramoto T; Daida H; Ikewaki K; Maeda Y; Nakagomi M; Shirakawa M; Kakikawa T; Numaguchi H; Johnson-Levonas AO; Vaidya S; Blaustein RO
    Atherosclerosis; 2016 Jun; 249():215-23. PubMed ID: 27131642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HDL and CETP in atherogenesis].
    Pöss J; Böhm M; Laufs U
    Dtsch Med Wochenschr; 2010 Feb; 135(5):188-92. PubMed ID: 20082258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.